Needham & Company raised estimates and its price target on Gilead Sciences (NASDAQ: GILD) from $62 to $70 following Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE